LT2555775T - Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure - Google Patents
Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressureInfo
- Publication number
- LT2555775T LT2555775T LTEP11757063.0T LT11757063T LT2555775T LT 2555775 T LT2555775 T LT 2555775T LT 11757063 T LT11757063 T LT 11757063T LT 2555775 T LT2555775 T LT 2555775T
- Authority
- LT
- Lithuania
- Prior art keywords
- adenosine
- agonists
- intraocular pressure
- carbonic anhydrase
- anhydrase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31572110P | 2010-03-19 | 2010-03-19 | |
PCT/US2011/029010 WO2011116290A1 (en) | 2010-03-19 | 2011-03-18 | Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2555775T true LT2555775T (en) | 2017-04-25 |
Family
ID=44649619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP11757063.0T LT2555775T (en) | 2010-03-19 | 2011-03-18 | Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure |
Country Status (17)
Country | Link |
---|---|
US (1) | US8440639B2 (en) |
EP (1) | EP2555775B1 (en) |
JP (1) | JP2013522322A (en) |
CN (1) | CN102933220A (en) |
CY (1) | CY1118495T1 (en) |
DK (1) | DK2555775T3 (en) |
ES (1) | ES2613254T3 (en) |
HR (1) | HRP20170008T1 (en) |
HU (1) | HUE031529T2 (en) |
LT (1) | LT2555775T (en) |
ME (1) | ME02593B (en) |
PL (1) | PL2555775T3 (en) |
PT (1) | PT2555775T (en) |
RS (1) | RS55617B1 (en) |
SI (1) | SI2555775T1 (en) |
SM (1) | SMT201700019B (en) |
WO (1) | WO2011116290A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2424546E (en) * | 2009-05-01 | 2015-12-23 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans |
EP2523669B1 (en) * | 2010-01-11 | 2016-12-07 | Inotek Pharmaceuticals Corporation | Combination, kit and method of reducing intraocular pressure |
SG184221A1 (en) * | 2010-03-26 | 2012-10-30 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
HUE035750T2 (en) * | 2012-01-26 | 2018-05-28 | Inotek Pharmaceuticals Corp | Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof |
US9522160B2 (en) | 2013-03-15 | 2016-12-20 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
JP2018501219A (en) * | 2014-12-03 | 2018-01-18 | イノテック ファーマシューティカルズ コーポレイション | How to prevent, reduce or treat macular degeneration |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7423144B2 (en) * | 2004-05-26 | 2008-09-09 | Inotek Pharmaceuticals Corporation | Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof |
CN101010085B (en) | 2004-05-26 | 2012-12-26 | 伊诺泰克制药公司 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof |
CN101321460A (en) * | 2005-11-30 | 2008-12-10 | 伊诺泰克制药公司 | Purine derivatives and methods of use thereof |
PT2424546E (en) * | 2009-05-01 | 2015-12-23 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans |
-
2011
- 2011-03-18 RS RS20170065A patent/RS55617B1/en unknown
- 2011-03-18 EP EP11757063.0A patent/EP2555775B1/en active Active
- 2011-03-18 US US13/051,633 patent/US8440639B2/en not_active Expired - Fee Related
- 2011-03-18 SI SI201131085A patent/SI2555775T1/en unknown
- 2011-03-18 PT PT117570630T patent/PT2555775T/en unknown
- 2011-03-18 HU HUE11757063A patent/HUE031529T2/en unknown
- 2011-03-18 CN CN2011800147015A patent/CN102933220A/en active Pending
- 2011-03-18 WO PCT/US2011/029010 patent/WO2011116290A1/en active Application Filing
- 2011-03-18 DK DK11757063.0T patent/DK2555775T3/en active
- 2011-03-18 ES ES11757063.0T patent/ES2613254T3/en active Active
- 2011-03-18 LT LTEP11757063.0T patent/LT2555775T/en unknown
- 2011-03-18 ME MEP-2017-12A patent/ME02593B/en unknown
- 2011-03-18 JP JP2013500232A patent/JP2013522322A/en active Pending
- 2011-03-18 PL PL11757063T patent/PL2555775T3/en unknown
-
2017
- 2017-01-04 HR HRP20170008TT patent/HRP20170008T1/en unknown
- 2017-01-16 SM SM201700019T patent/SMT201700019B/en unknown
- 2017-01-25 CY CY20171100110T patent/CY1118495T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2555775B1 (en) | 2016-12-07 |
SI2555775T1 (en) | 2017-05-31 |
RS55617B1 (en) | 2017-06-30 |
US8440639B2 (en) | 2013-05-14 |
JP2013522322A (en) | 2013-06-13 |
HRP20170008T1 (en) | 2017-03-10 |
PL2555775T3 (en) | 2017-08-31 |
EP2555775A4 (en) | 2013-08-28 |
ME02593B (en) | 2017-06-20 |
US20110245193A1 (en) | 2011-10-06 |
CN102933220A (en) | 2013-02-13 |
DK2555775T3 (en) | 2017-02-06 |
WO2011116290A1 (en) | 2011-09-22 |
HUE031529T2 (en) | 2017-07-28 |
PT2555775T (en) | 2017-02-01 |
SMT201700019B (en) | 2017-03-08 |
EP2555775A1 (en) | 2013-02-13 |
CY1118495T1 (en) | 2017-07-12 |
ES2613254T3 (en) | 2017-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225390A1 (en) | Boronates as arginase inhibitors and compositions and uses thereof | |
HK1246674A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
ZA201206223B (en) | Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof | |
EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
EP2558543A4 (en) | Coating compositions for packaging articles and methods of coating | |
EP2539348A4 (en) | Cephalosporin derivatives useful as -lactamase inhibitors and compositions and methods of use thereof | |
HK1202333A1 (en) | Combination of kinase inhibitors and uses thereof | |
HK1162352A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
IL214226A (en) | Inhibitors of beta-secretase and various aspects related thereto | |
HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
ZA201206456B (en) | Uses of dgati inhibitors | |
IL208403A0 (en) | Compositions and use of epas1 inhibitors | |
EP2667889A4 (en) | Wnt compositions and methods of use thereof | |
PL2555775T3 (en) | Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure | |
EP2536709A4 (en) | Prolylhydroxylase inhibitors and methods of use | |
IL227924B (en) | Compositions and methods of use for determination of he4a | |
ZA201207688B (en) | Compositions and methods for non-toxic delivery of antiprogestins | |
EP2445873A4 (en) | Protease inhibitors, compositions and methods of use | |
ZA201303855B (en) | Benzoxazepines as inhibitors of p13k/m tor and methods of their use and manufacture | |
LU91725B1 (en) | Novel uses of V-ATPASE inhibitors |